https://iaslc.org

IASLC | International Association for the Study of Lung CancerThe International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other th ...IASLC | International Association for the Study of Lung Cancer Skip to main content Utility menu Donate Join Member Login Search Learn About UsLearn About UsStrategic PlanBoard of DirectorsCommitteesAwardsHistoryStaffContactCareersSupport The MissionSupport The MissionBecome a MemberExplore Different Ways to GiveJoin IASLC's Partners for Thoracic Cancer CareRecognizing Our DonorsAccess Online Learning Conferences & EducationConferences & EducationConferencesWebinarsOnline Learning: Lung Cancer 360Lung Cancer Considered PodcastWCLC: World Conference on Lung CancerScience & ResearchScience & ResearchJournalsJournalsJournal of Thoracic OncologyJTO Clinical and Research Reports (JTO CRR)IASLC Reviewer WorkshopScientific ProjectsScientific ProjectsIASLC Staging Project: Lung Cancer, Thymic Tumors, and MesotheliomaIASLC Global Survey on Biomarker Testing in Lung Cancer 2024 UpdateIASLC Neoadjuvant Therapy in Lung Cancers InitiativesIASLC Atlas of Molecular Testing for Targeted Therapy in Lung CancerELICPast IASLC Scientific ProjectsResearch Grant ProgramResearch Grant ProgramResearch Grant RecipientsIASLC AcademyPublications, Resources & GuidelinesMembershipMembershipBecome a MemberRenew Your MembershipEarly-Career OpportunitiesPartners Society Membership OffersPatients & CaregiversPatients & CaregiversSTARS TrainingLung Cancer Awareness MonthNewsNewsIASLC Lung Cancer News WCLC 2024 NewsPress Releases Fulltext search Fulltext search Search WCLC 2025 Call for TalentSubmit now for the WCLC 2025 call for talent! Deadline April 16, 2025Submit Your PerformanceWCLC 2025 Early Bird RegistrationEarly-bird registration is now open! Save big & secure your place among global leaders in Barcelona this September!Register Now2025 Cancer Care Team AwardKnow a care team making a difference? Nominate them for the 2025 IASLC Cancer Care Team Award!Nominate NowPreviousNextWCLC 2025 Call for TalentWCLC 2025 Early Bird Registration2025 Cancer Care Team AwardPreviousNext Homepage Members Hub My Account Member Services Pay Dues Lung Cancer 360 Member Directory Member Login The International Association for the Study of Lung Cancer The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer. Explore More ILCN In Focus ILCN article Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress. Haleigh Behrman Apr 11, 2025 Read more ILCN article Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award Apr 11, 2025 ILCN article Smoking Cessation in Lung Cancer Screening: The Latest Randomized Controlled Trial Evidence Apr 11, 2025 ILCN article From Grief to Global Change: How the STARS Program Empowers Advocates to Drive Lung Cancer Research Apr 11, 2025 ILCN article Foritinib Gains Momentum in China for ALK-positive NSCLC Haleigh Behrman Apr 11, 2025 IASLC's Annual Report 2023 2023 was a year of growth focused on expanding our projects and providing our community with more resources than ever before. Read our full report below.  View the full Report IASLC's Visionary Strategic Plan for the Next Five Years In the ever-evolving landscape of lung cancer research and patient care, we have embarked on a transformative journey by unveiling a new strategic plan that redefines its mission and objectives for the next five years. Learn More IASLC Position Statement on the Documentation of Tobacco Use in Cancer Clinical Trials The IASLC TCSC Committee recently issued an official position statement on the documentation of tobacco use in clinical trials. They note in recent years, there has been growing awareness of the negative impact of tobacco use on clinical outcomes for cancer patients. The 2014 U.S. Surgeon General’s report compiled compelling evidence that cigarette smoking by cancer patients and survivors causes adverse outcomes, including increased all-cause mortality, cancer-specific mortality, and increased risk of a second primary cancer. Furthermore, smoking clearly affects survival and the toxicity of cancer treatments, and these endpoints serve as the primary or secondary objectives of virtually all clinical trials. As a result, it is critical that smoking information be collected and available for analysis to accurately assess the benefits and harms of cancer treatment in clinical trials. Read the Position Statement IASLC's STARS Program The STARS Program (Supportive Training for Advocates on Research & Science) was formed in 2019 to address this need. A collaboration composed of patient and professional lung cancer research advocates and lung cancer advocacy organizations designed STARS to help patient advocates evolve into patient research advocates (PRAs), increasing the number of PRAs equipped to provide accurate scientific translation in their online or real-life groups for people living with lung cancer, and enabling more people to provide the patient perspective for lung cancer research and policy.  Explore More IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective.    Access the Latest Atlas IASLC's Corporate Roundtable Born from feedback received during meetings with our Corporate Partners in 2022, the IASLC Partners for Thoracic Cancer Care brings IASLC leadership and Roundtable Member Representatives together to collaborate on solutions to big-picture challenges facing those working to conquer lung cancer and other thoracic malignancies.  Learn More Our Impact 11,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide within the 21st century. Our Work The IASLC Staging ProjectThe IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.Explore MoreLung Cancer Policy Network MapProvide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.ExplorePreviousNext In Numbers 8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide. 45 Years Experience 15K Number of Research Awards Funded 20.121 JTO Impact Factor 8K+ MembersPreviousNext Lung Cancer Policy Network MapProvide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.ExploreThe IASLC Staging ProjectThe IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.Explore moreIASLC Neoadjuvant Therapy in Lung Cancers InitiativesThe IASLC is working to address key knowledge gaps in clinical practice related to the use of neoadjuvant therapies in lung cancer through the establishment of the IASLC Neoadjuvant Therapy in Lung Cancers Initiative. These projects aim to knowledge gaps by providing clear definitions and guidance for the lung cancer community to rely on , with the ultimate goal of establishing pathologic response in surgical resection specimens following neoadjuvant therapies (MPR and pCR) as predictors of long-term clinical benefit in patients with stages I to III lung cancers. ExplorePreviousNext In numbers 11,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide in the 21st century. 45 Years Experience 15K Number of Research Awards Funded 20.4 JTO Impact Factor 8K+ MembersPreviousNext Upcoming Meetings & Webinars View all Upcoming Events IASLC Meeting Sep 06 - Sep 09 2025 IASLC 2025 World Conference on Lung Cancer | Barcelona IASLC Webinar Apr 24 - Apr 24 2025 Apr 24, 2025 Smoking Cessation at Lung Examination: Lessons Learned and Next Steps from the NCI SCALE Collaboration - Part 2 Endorsed Event May 08 - May 09 2025 May 8-9, 2025 3rd Edition Artificial Intelligence for Oncology CME Accredited Endorsed Event Jul 25 - Jul 26 2025 July 25 - 26, 2025 26th Annual International Lung Cancer Congress® CME Accredited IASLC Meeting Oct 09 - Oct 11 2025 October 9-11, 2025 2025 Asia Conference on Lung Cancer CME Accredited IASLC Meeting Nov 21 - Nov 23 2025 November 21-23, 2025 2025 Hot Topic: Unraveling Precancer and Early-stage Lung Cancer - From Biology to Clinical Application Joint Event Dec 05 - Dec 07 2025 December 5-7, 2025 2025 North America Conference on Lung Cancer IASLC Meeting Feb 18 - Feb 21 2026 February 18-21, 2026 2026 Targeted Therapies of Lung Cancer Joint Event Mar 25 - Mar 28 2026 March 25 – 28, 2026 2026 European Lung Cancer Congress IASLC Meeting Sep 12 - Sep 15 2026 September 12 – 15, 2026 2026 World Conference on Lung Cancer Pagination Page 1 Next page ›› Journal of Thoracic Oncology & JTO Clinical and Research Reports Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.  https://www.jto.org/article/S1556-0864(23)02310-9/fulltext JTO The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer James Huang +more Jan 30, 2025 https://www.jto.org/article/S1556-0864(24)00079-0/fulltext JTO The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer Jan 30, 2025 https://www.jto.org/article/S1556-0864(23)02293-1/fulltext?rss=yes JTO Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study Oct 10, 2023 https://www.jto.org/article/S1556-0864(23)02411-5/abstract JTO The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer Paul Van Schil +more Jan 30, 2025 https://www.jto.org/article/S1556-0864(23)02264-5/fulltext?rss=yes JTO Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer Katerina Politi +more Oct 04, 2023 https://www.jto.org/article/S1556-0864(24)00060-1/fulltext JTO The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer Jan 30, 2025 https://www.jto.org/article/S1556-0864(23)02423-1/fulltext JTO Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer Jan 30, 2025 https://www.jto.org/article/S1556-0864(24)00032-7/fulltext JTO Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study Jan 30, 2025 Explore Our Journals Stay Connected X Facebook Linkedin Youtube Instagram WeChat SoundCloud Spotify Apple Podcasts Home IASLC Sites 2024 WCLC JTO JTO CRR ILCN Member Portal IASLC STARS Lung Cancer 360 Footer Careers Facebook Instagram LinkedIn X WeChat YouTube Apple Podcasts SoundCloud Spotify Privacy Policy Terms & Conditions User Login Bylaws © 2025 IASLC © 2025 IASLCenen1774230964https://iaslc.org

Ahitsio ny tranokalanao?

Manao inona ianao?